Our attorneys regularly represent venture capital, corporate and angel investors as well as growing companies in a wide range of financing transactions, including:

  • Early stage seed rounds
  • Convertible debt financing
  • Institutional venture rounds
  • Syndicated investment special purpose vehicles
  • Broker and company sold private placements
  • Secondary sales of portfolio companies
  • Secondary sales of partnership interest
  • Investor representation in connection with disposition or IPO of portfolio companies

Clients include venture capital funds, strategic corporate investors, hedge funds and angel investors, start-up companies and other rapid growth enterprises.

We understand the market within which venture capital transactions operate. We have developed a strong practice by delivering the highest caliber of work while being able to respond to our clients’ need to complete transactions in a timely and cost-effective manner.

Our deep experience with private financing transactions and solid understanding of the venture capital industry has guided our development of a disciplined, process driven approach to venture capital and angel financing transactions. Whether representing an investor or company we:

  • Understand that your objective is our success, so we start every engagement with one question—what do you hope to achieve?
  • Create a transaction plan, schedule and team to meet your objectives
  • Ensure that senior legal leadership is heavily involved in your transaction
  • Utilize a disciplined and methodical document drafting, review and negotiation process
  • Provide structured due diligence review and disclosure review process


We have closed thousands of private financing transactions with an aggregate value in excess of $2 billion.

Representative Cases

  • Over $2 billion in venture financings
  • Represented $1 billion plus venture firm in over 200 investments
  • Represented Fortune 100 retailer’s corporate venture capital group in numerous venture investments
  • Represented Fortune 500 medical device company in numerous venture investments
  • Represented numerous venture investors throughout U.S. in seed stage, venture and late stage investments
  • Represented investors in secondary acquisition of portfolio securities
  • Represented venture investors in over $1 billion in exit transactions


Main Contact

News & Insights

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.